OGEN ORAGENICS INC
Price Chart
Executive Summary
Oragenics signed a non-binding Letter of Intent to license CardioDialysis, an extracorporeal blood purification technology, from Sigyn Therapeutics for TBI and neurodegenerative diseases. The deal includes issuing 3.25M convertible preferred shares (1:1 to common) and a 3% royalty on future sales, but remains subject to due diligence, board approvals, and NYSE American listing compliance. With no FDA-approved treatments for mTBI, the platform strategy is promising but early-stage and contingent on many closing conditions.
Actionable Insight
Monitor for definitive agreement, shareholder vote date, and NYSE American approval. The stock may trade on deal progress and clinical updates for ONP-002. Given the non-binding nature and historical volatility, position sizing should account for binary risk.
Key Facts
- Oragenics signed a LOI to license CardioDialysis from Sigyn Therapeutics for TBI and neurodegenerative disorders.
- Consideration: 3,250,000 shares of a new class of restricted preferred stock, convertible 1:1 to common, subject to shareholder and exchange approvals.
- Oragenics would pay a 3% royalty on sales for six years after first commercial sale per indication/country.
- Target closing within 90 days; LOI is non-binding except for exclusivity, confidentiality, and governing law provisions.
- The license would complement Oragenics' Phase IIa intranasal neurosteroid ONP-002 for mTBI, creating a dual-modality approach to TBI inflammation.
- There are currently no FDA-approved pharmacological treatments for concussion or mTBI; 69 million people worldwide suffer brain injury annually.
Financial Impact
3.25 million shares of convertible preferred stock as consideration; 3% royalty on future net sales (no current revenue or sales projections provided).
Risk Factors
- Definitive agreement may not be executed; due diligence or board approvals could fail.
- Shareholder approval and NYSE American continued listing conditions may not be met.
- Significant dilution from 3.25M convertible shares relative to current market cap ($3M).
- No clinical or commercial data for CardioDialysis in TBI; regulatory pathway uncertain.
- Historical stock performance shows high volatility with negative average returns on prior filings.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-021627 |
| Exhibit: ex99-1.htm | 0001493152-26-021627 |
| Document: 0001493152-26-021627-index-headers.html | 0001493152-26-021627 |
| Document: 0001493152-26-021627-index.html | 0001493152-26-021627 |
| Document: 0001493152-26-021627.txt | 0001493152-26-021627 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
20d ago
|
DEFA14A
| $0.5900 $0.6100 | ▲ +3.39% | ▲ +1.54% | $0.6000 (+1.69%) |
|
May 19, 2026
21d ago
|
8-K
| $0.5700 $0.5999 | ▲ +5.25% | ▲ +3.00% | $0.6000 (+5.26%) |
|
May 7, 2026
4w ago
|
8-K
| $0.6100 $0.5700 | ▼ −6.56% | ▼ −8.06% | $0.6000 (−1.64%) |
|
Apr 13, 2026
8w ago
|
8-K
| $0.6800 $0.7100 | ▲ +4.41% | ▲ +1.12% | $0.6000 (−11.76%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $0.5800 $0.5600 | ▲ +3.45% | ▲ +5.08% | $0.6000 (−3.45%) |
|
Mar 23, 2026
11w ago
|
EFFECT
| $0.6800 $0.5000 | ▼ −26.47% | ▼ −22.91% | $0.6000 (−11.76%) |
|
Mar 11, 2026
12w ago
|
8-K
| $0.9600 $0.7500 | ▼ −21.88% | ▼ −20.90% | $0.6000 (−37.50%) |
|
Mar 11, 2026
12w ago
|
Press Release
| $0.8800 $0.7900 | ▼ −10.23% | ▼ −8.04% | $0.6000 (−31.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access